A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J. F. Belch,
Deborah P. M. Symmons, on behalf of
the TRACE RA Consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Pete Tags: Original Article Source Type: research
More News: Arthritis | Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | Heart Attack | Ischemic Stroke | Lipitor | Rheumatoid Arthritis | Rheumatology | Statin Therapy | Stroke | Study | Zivast